![]() |
|
|
Vol. 291, Issue 2, 705-709, November 1999
Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto, Japan
| |
Abstract |
|---|
|
|
|---|
Peptide transporters (PEPT1 and PEPT2) in epithelia play an important role in the absorption of small peptides and peptide-like drugs. Recently, it was demonstrated that various nonpeptidic compounds can be transported by these transporters. In the present study, we focused on the L-amino acid ester compounds and examined the mechanisms of their interaction with rat PEPTs (rPEPTs) using stable transfectants. Valacyclovir, the L-valyl ester prodrug of the antiherpetic agent acyclovir, competitively inhibited [14C]glycylsarcosine uptake in the rPEPT1- or rPEPT2-expressing cells. Dixon plot analyses showed that the inhibition constant (Ki) values of valacyclovir were 2.7 and 0.22 mM for rPEPT1 and rPEPT2, respectively, suggesting that rPEPT2 had higher affinity for this agent. Various L-valine alkyl esters significantly inhibited [14C]glycylsarcosine uptake. L-Valine methyl ester (Val-OMe) competitively inhibited [14C]glycylsarcosine uptake with Ki values of 3.6 and 0.83 mM for rPEPT1 and rPEPT2, respectively, indicating that Val-OMe is also a high-affinity substrate for rPEPT2. Val-OMe had a trans-stimulation effect on [14C]glycylsarcosine efflux from both transfectants, suggesting the translocation of L-valine methyl ester via rPEPTs. Val-OMe showed the most potent inhibitory effect among the several L-amino acid methyl esters examined. We conclude that Val-OMe, as well as valacyclovir, could be recognized and transported by rPEPT1 and rPEPT2 and that these L-valyl esters showed higher affinity for rPEPT2 as do most substrates of these transporters. Our results suggest that L-valine is a desirable L-amino acid for the esterification of poorly permeable drugs to enhance their oral bioavailability targeting intestinal PEPT1.
| |
Introduction |
|---|
|
|
|---|
Peptide
transporters (PEPT1 and PEPT2) play an important role in the
maintenance of protein nutrition by mediating the transport of
dipeptides and tripeptides across the brush-border membranes in the
small intestine and kidney (Leibach and Ganapathy, 1996
; Daniel and
Herget, 1997
). Due to their broad substrate specificity, PEPT1 and
PEPT2 are able to transport various peptide-like drugs structurally
related to small peptides such as
-lactam antibiotics (Ganapathy et
al., 1995
; Saito et al., 1995
; Terada et al., 1997b
) and the anticancer
agent bestatin (Saito et al., 1996
). In addition, intestinal PEPT was
used to improve the intestinal absorption of poorly absorbed
pharmacologically active amino acid analogs through the production of
dipeptidyl derivatives (Hu et al., 1989
; Tsuji et al., 1990
).
Therefore, the determination of the structural requirements for
substrate recognition of PEPTs is important for the molecular design of
pharmacologically active peptide-like drugs and prodrugs.
Recently, valacyclovir, the L-valyl ester of the
antiherpetic agent acyclovir, was demonstrated to be transported by
intestinal PEPT1 (Balimane et al., 1998
; Han et al., 1998a
,b
). The
bioavailability of acyclovir after oral valacyclovir administration was
considerably greater than that after oral administration of acyclovir
(Perry and Faulds, 1996
). Therefore, L-valyl esterification
seems to be a very useful strategy for improving the intestinal
absorption of drugs with low oral bioavailability. However, it has not
been fully understood whether other L-amino acid ester
compounds, as well as valacyclovir, are recognized by PEPTs. Such
information will provide the molecular basis for a rational design of
oral prodrugs targeting the intestinal PEPT1. In addition, there is little information about the interaction of L-amino acid
ester compounds with PEPT2. A comparison of this interaction between PEPT1 and PEPT2 will be important to characterize the biological aspects of the PEPTs.
The aim of this study was to gain more information regarding the interaction of L-amino acid ester compounds with PEPTs. We examined the effects of valacyclovir and a series of L-amino acid alkyl esters on [14C]glycylsarcosine uptake by rat PEPT1- or PEPT2-expressing transfectant. Furthermore, we focused L-valine methyl ester (Val-OMe) as a typical of L-amino acid alkyl ester and investigated its inhibition kinetics and trans-stimulation effect on [14C]glycylsarcosine uptake by both sets of transfectants.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials. Valacyclovir was supplied by Glaxo Wellcome Research and Development (Hertfordshire, UK). [14C]Glycylsarcosine (1.78 GBq/mmol) was obtained from Daiichi Pure Chemicals Co., Ltd. (Ibaraki, Japan). All L-valine alkyl esters were purchased from Sigma Chemical Co. (St. Louis, MO). L-Alanine- and L-phenylalanine methyl esters were obtained from Nacalai Tesque (Kyoto, Japan). Other L-amino acid methyl esters were obtained from Sigma Chemical Co. All other chemicals used were of the highest purity available.
Cell Culture.
The parental LLC-PK1 cells were
obtained from American Type Culture Collection (ATCC CRL-1392;
Rockville, MD). The LLC-PK1 cells transfected with rPEPT1
cDNA (LLC-rPEPT1) or with rPEPT2 cDNA (LLC-rPEPT2) were constructed as
described previously (Terada et al., 1997a
,b
). These transfectants were
cultured in complete medium consisting of Dulbecco's modified Eagle's
medium (Gibco Life Technologies, Grand Island, NY) supplemented with
10% FBS (Whittaker Bioproducts Inc., Walkersville, MD) with G418
(Gibco) in an atmosphere of 5% CO2/95% air at 37°C. In
the uptake experiments, the cells were cultured for 6 days in complete
medium without G418.
Uptake Studies by Cell Monolayers.
The uptake of
[14C]glycylsarcosine was measured in cells grown on 35-mm
plastic dishes as described previously (Terada et al., 1997b
). The
protein contents of cell monolayers solubilized in 1 N NaOH were
determined according to the method of Bradford (1976)
with a Bio-Rad
(Hercules, CA) protein assay kit with bovine
-globulin as the standard.
Statistical Analysis. Data were analyzed statistically with nonpaired t test or one-way ANOVA, followed by Scheffé's test when multiple comparisons were needed.
| |
Results |
|---|
|
|
|---|
Interaction of Valacyclovir with PEPTs.
Previously, we
established and characterized rPEPT1- or rPEPT2-expressing transfectant
(LLC-rPEPT1 and LLC-rPEPT2 cells, respectively; Terada et al.,
1997a
,b
). With the use of these transfectants, the mechanism involved
in the interaction of valacyclovir with rPEPT1 and rPEPT2 was examined.
As shown in Fig. 1, A and B, valine and
acyclovir, which are constituents of valacyclovir, had no inhibitory
effect, whereas valacyclovir had a potent inhibitory effect on
[14C]glycylsarcosine uptake by both transfectants. The
inhibition kinetics of valacyclovir on
[14C]glycylsarcosine uptake revealed that valacyclovir
was found to decrease the affinity of glycylsarcosine for the
transporters (Km values for control versus
those in the presence of valacyclovir = 1.9 ± 0.1 versus
3.2 ± 0.3 mM for rPEPT1 and 0.09 ± 0.01 versus 0.15 ± 0.03 mM for rPEPT2). In contrast, the maximal velocities showed no
significant changes (Vmax values for control
versus those in the presence of valacyclovir: 66 ± 2 versus
62 ± 5 nmol/mg protein/15 min for rPEPT1 and 1.1 ± 0.1 versus 1.0 ± 0.2 nmol/mg protein/15 min for rPEPT2). These
results showed that valacyclovir competitively inhibited
[14C]glycylsarcosine uptake by both rPEPT1 and rPEPT2.
|
Interaction of L-Valine Alkyl Esters with PEPTs.
To clarify whether other ester compounds are recognized by rPEPT1 and
rPEPT2, we next investigated the interactions of a series of
L-amino acid alkyl esters with both transporters. We first examined the effects of L-valine alkyl esters on
[14C]glycylsarcosine uptake by LLC-rPEPT1 and LLC-rPEPT2
cells. As shown in Fig. 2,
[14C]glycylsarcosine uptake by both transfectants was
inhibited by various L-valine alkyl esters, as well as by
valacyclovir, but not by valine.
|
Inhibition Kinetics and trans-Stimulation Effect of
Val-OMe.
Because Val-OMe was the smallest molecule of the
L-valine alkyl esters examined, we were interested in this
compound to study the minimal structural requirements for the
recognition by PEPTs and examined its inhibition kinetics on
[14C]glycylsarcosine uptake by both transfectants. As
shown in the insets in Fig. 3, the
presence of Val-OMe decreased the affinity of glycylsarcosine to the
transporters (Km values for control versus
in the presence of Val-OMe: 1.7 ± 0.02 versus 3.1 ± 0.09 mM
for rPEPT1 and 0.07 ± 0.003 versus 0.16 ± 0.03 mM for
rPEPT2). The maximal velocities were not significantly changed
(Vmax values for control versus in the
presence of Val-OMe: 57 ± 3 versus 53 ± 3 nmol/mg
protein/15 min for rPEPT1 and 1.0 ± 0.1 versus 0.9 ± 0.2 nmol/mg protein/15 min for rPEPT2). These results showed that Val-OMe
competitively inhibited [14C]glycylsarcosine uptake by
both rPEPT1 and rPEPT2, as well as by valacyclovir.
|
|
|
Interaction of L-Amino Acid Methyl Esters with
PEPTs.
Finally, we examined the effects of various
L-amino acid derivatives of methyl ester on
[14C]glycylsarcosine uptake by LLC-rPEPT1 and LLC-rPEPT2
cells. As shown in Fig. 6,
[14C]glycylsarcosine uptake by LLC-rPEPT1 cells was
inhibited markedly by the presence of Val-OMe or
L-isoleucine methyl ester. On the other hand, in LLC-rPEPT2
cells, L-valine, L-leucine, and
L-isoleucine methyl ester potently inhibited
[14C]glycylsarcosine uptake.
|
| |
Discussion |
|---|
|
|
|---|
It has been believed that peptide bonds are required for
recognition by PEPTs as substrates. However, recent investigations have
demonstrated that various compounds with no peptide bonds, such as
4-aminophenylacetic acid (Temple et al., 1998
),
-aminolevulinic acid
(which has a ketomethylene group instead of peptide bond; Döring
et al., 1998a
), and
-amino fatty acids with more than 4CH2 units in the backbone (Döring et al.,
1998b
), are recognized and transported by PEPTs. Valacyclovir, the
L-valyl ester prodrug of the antiherpetic agent acyclovir,
has also shown to interact with PEPTs (Balimane et al., 1998
; Ganapathy
et al., 1998
; Han et al., 1998a
,b
). Oral administration of valacyclovir
produced a greater increase in urinary excretion of acyclovir (63%),
compared with oral administration of acyclovir (19%; Perry and Faulds, 1996
). Therefore, this prodrug strategy could be very useful to improve
the oral bioavailability of poorly absorbed drugs. In the present
study, to obtain general information about the interaction of
L-amino acid ester derivatives with PEPTs, we selected
L-valyl ester compounds and examined their recognition and
transport by rPEPT1 and rPEPT2.
The present study demonstrated that
[14C]glycylsarcosine uptake by rPEPT1- or
rPEPT2-expressing transfectants was inhibited by various
L-valine alkyl esters, as well as by valacyclovir, but not
by L-valine. These findings suggested that
L-valyl ester compounds generally interact with PEPTs. We
examined the inhibition kinetics and trans-stimulation
effect of Val-OMe on [14C]glycylsarcosine
uptake by both transfectants. The results suggested that Val-OMe and
glycylsarcosine shared a common binding site and transport pathway in
rPEPT1 and rPEPT2. These findings also suggested that Val-OMe is
transported by both transporters. Although we did not directly measure
the transport of this compound, the Val-OMe transport by rPEPT1 and
rPEPT2 was supported by the previous reports of direct measurement of
valacyclovir uptake via PEPT1 (Balimane et al., 1998
; Han et al.,
1998a
,b
) and the present results concerning the
trans-stimulation effect of L-valine
benzyl ester.
Val-OMe was a probable substrate for the PEPTs, whereas
L-valine was not. The only difference in the chemical
structures of these compounds is COO
versus
COOCH3. These findings raised the question of how
the transporters discriminate between these two compounds. The size or
configuration of the ester methyl group of Val-OMe may be an important
determinant for recognition by PEPTs. Alternatively, the carboxylic
anion charge of L-valine might interfere with the interaction with PEPTs. The precise mechanisms of the different interactions of L-valine and Val-OMe with PEPTs were
unclear based on the results of the present study, and further studies
are needed to clarify these issues. Recently, using a series of
-amino fatty acids as model compounds, Döring et al. (1998b)
demonstrated that 5-amino pentanoic acid satisfied the minimal
structural requirements for substrates of rabbit PEPT1. Considering the
differences of L-valine and Val-OMe, it should be
reasonable that Val-OMe is also one of the substrates to satisfy the
minimal structural requirements.
Beauchamp et al. (1992)
evaluated the bioavailability of 18 ester
compounds, including amino acid ester compounds, of acyclovir during
the course of development of prodrugs for acyclovir. They found that
the L-valyl ester provided the best acyclovir
bioavailability, followed by the L-isoleucyl,
L-alanyl, glycyl, and L-leucyl esters. This
order was comparable with the inhibitory potencies of
L-amino acid methyl esters on
[14C]glycylsarcosine uptake by
rPEPT1-expressing cells in the present study. Therefore, the findings
of Beauchamp et al. (1992)
may reflect the affinities of these
compounds to intestinal PEPT1. In support of these suggestions, glycyl
ester acyclovir showed less transport by human PEPT1 than the
L-valyl ester acyclovir valacyclovir (Han et al., 1998a
,b
).
Taken together, interaction potencies of L-amino acid ester
compounds with PEPTs were dependent on L-amino acids, and
L-valine was suggested to be a preferable L-amino acid for this purpose.
A comparison of Ki values showed that both
valacyclovir and Val-OMe had higher affinity for rPEPT2 than for
rPEPT1. These findings were comparable with those of previous reports
that PEPT2 showed higher affinity for chemically diverse dipeptides
(Ramamoorthy et al., 1995
) and amino
-lactam antibiotics (Ganapathy
et al., 1995
; Terada et al., 1997b
) compared with PEPT1. Therefore, the peptide bonds appear to not be important for determination of the
affinity of both transporters. We previously demonstrated that the
-amino group of substrates was one of the determinants for the high
affinity interaction with rPEPT2 (Terada et al., 1997b
). Because both
valacyclovir and Val-OMe have a free
-amino group originating from
L-valine, our assumption was shown to be true in this case.
In conclusion, we demonstrated that valacyclovir and Val-OMe are recognized by rPEPT1 and rPEPT2 and that valacyclovir and Val-OMe showed higher affinity for rPEPT2 than for rPEPT1. These findings suggest that L-valyl ester compounds can be generally accepted as substrates of PEPT1 and PEPT2, similar to other substrates of PEPTs. From the viewpoint of drug delivery system, L-valyl esterification of poorly absorbed drugs may be a useful and developmental strategy for improving their intestinal absorption.
| |
Footnotes |
|---|
Accepted for publication August 5, 1999.
Received for publication May 27, 1999.
1 This work was supported in part by a Grant-in-Aid for Scientific Research (B) and a Grant-in-Aid for Scientific Research on Priority Areas of "Bio-molecular Design for Biotargeting" (11132235) from the Ministry of Education, Science, Sports, and Culture of Japan and by grants from the Uehara Memorial Foundation and from the Yamada Science Foundation.
Send reprint requests to: Prof. Ken-ichi Inui, Ph.D., Department of Pharmacy, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan. E-mail: inui{at}kuhp.kyoto-u.ac.jp
| |
Abbreviations |
|---|
PEPT, peptide transporter; rPEPT, rat peptide transporter; Val-OMe, L-valine methyl ester.
| |
References |
|---|
|
|
|---|
-lactam antibiotics by intestinal and renal peptide transporters, PEPT1 and PEPT2.
J Biol Chem
270:
25672-25677
-methyldopa: Carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-
-methyldopa.
Pharm Res
6:
66-70[Medline].
-lactam antibiotics in the intestine and kidney.
J Pharmacol Exp Ther
275:
1631-1637
-lactam antibiotics.
J Pharmacol Exp Ther
281:
1415-1421[Abstract].
-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
Am J Physiol
273:
F706-F711
-methyldopa-Phe in intestinal brush-border membrane vesicles.
Pharm Res
7:
308-309[Medline].
This article has been cited by other articles:
![]() |
E. J. Perkins and T. Abraham Pharmacokinetics, Metabolism, and Excretion of the Intestinal Peptide Transporter 1 (SLC15A1)-Targeted Prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-Amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in Rats and Dogs: Assessment of First-Pass Bioactivation and Dose Linearity Drug Metab. Dispos., October 1, 2007; 35(10): 1903 - 1909. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tsuda, T. Terada, M. Irie, T. Katsura, A. Niida, K. Tomita, N. Fujii, and K.-i. Inui Transport Characteristics of a Novel Peptide Transporter 1 Substrate, Antihypotensive Drug Midodrine, and Its Amino Acid Derivatives J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 455 - 460. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Bhardwaj, D. Herrera-Ruiz, P. J. Sinko, O. S. Gudmundsson, and G. Knipp Delineation of Human Peptide Transporter 1 (hPepT1)-Mediated Uptake and Transport of Substrates with Varying Transporter Affinities Utilizing Stably Transfected hPepT1/Madin-Darby Canine Kidney Clones and Caco-2 Cells J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1093 - 1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Irie, T. Terada, T. Katsura, S. Matsuoka, and K.-i. Inui Computational modelling of H+-coupled peptide transport via human PEPT1 J. Physiol., June 1, 2005; 565(2): 429 - 439. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Anand, J. Patel, and A. K. Mitra Interactions of the Dipeptide Ester Prodrugs of Acyclovir with the Intestinal Oligopeptide Transporter: Competitive Inhibition of Glycylsarcosine Transport in Human Intestinal Cell Line-Caco-2 J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 781 - 791. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kottra, A. Stamfort, and H. Daniel PEPT1 as a Paradigm for Membrane Carriers That Mediate Electrogenic Bidirectional Transport of Anionic, Cationic, and Neutral Substrates J. Biol. Chem., August 30, 2002; 277(36): 32683 - 32691. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Wenzel, S. Kuntz, and H. Daniel Flavonoids with Epidermal Growth Factor-Receptor Tyrosine Kinase Inhibitory Activity Stimulate PEPT1-Mediated Cefixime Uptake into Human Intestinal Epithelial Cells J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 351 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Irie, T. Terada, K. Sawada, H. Saito, and K.-I. Inui Recognition and Transport Characteristics of Nonpeptidic Compounds by Basolateral Peptide Transporter in Caco-2 Cells J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 711 - 717. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||